Compare Lululemon Athletica Inc (LULU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs TG Therapeutics Inc — how do they compare? Lululemon Athletica Inc trades at $94.5 (market cap $10.27B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Lululemon Athletica Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 105 Days and TG Therapeutics Inc for 16 Days on average.
| LULU | TGTX | |
|---|---|---|
Market Cap | $10.27B | $8.16B |
Volume | 4,392,324 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $59.06 |
52-Week Low | $91.88 | $26.94 |
Typical Hold Time | 105 Days | 16 Days |
Enterprise Value | $11.02B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon (LULU) stock trades at $92.68, down 54% year-to-date and near its 52-week low. The technical outlook is bearish, while fundamentals show strong profitability with a 56.11% gross margin and a low P/E of 7.63. Recent earnings beats are overshadowed by a revenue decline and multiple securities fraud investigations announced in late September 2026.
The stock presents a value opportunity based on depressed valuation multiples, but significant risks exist from legal scrutiny, competitive pressures, and weakening growth. Analyst consensus is a 'Hold' with a $97.67 price target, indicating cautious optimism amid high uncertainty.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
